MSLN and neoplasm: In addition, a significant reduction of MSLN-positive tumor masses was observed in mice treated with a combination of MSLN490 and standard chemotherapeutics (i.e., paclitaxel), suggesting that this strategy is promising even for solid tumors with low immune cell infiltration [11].